V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240002375 | 240008485 | 1.7 | 92.6 | null | 2020-03-01 | 2020-03-01 | R Chlorambucil | 02 | null | CYCLOPHOSPHAMIDE | 101013499 |
| 240002377 | 240008486 | 1.77 | 73.2 | null | null | 2021-06-11 | LEAM | null | null | AML MYECHILD 01 TRIPLE IT | 101605120 |
| 240002384 | 240008487 | 1.82 | 76.3 | Curative (C) | 2019-11-15 | 2019-11-23 | FLAIR trial | 02 | N | AML16 TRIAL | 101289571 |
| 240002386 | 240008488 | 1.6 | 83.7 | null | 2017-07-12 | 2017-07-20 | null | N | null | GEMTUZUMAB OZOGAMICIN | 100377782 |
| 240002387 | 240008489 | 1.63 | 52.6 | null | 2019-08-08 | 2019-10-17 | CVP R | 02 | null | RUXOLITINIB | 101201039 |
| 240002389 | 240008490 | 1.78 | 77.4 | Adjuvant (A) | 2019-08-24 | 2019-09-02 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | null | OBINUTUZUMAB | 100804433 |
| 240002391 | 240008491 | 1.67 | 97 | null | 2019-01-11 | 2019-03-07 | ALL UKALL2011 Maintenance B1 | 02 | null | ANAGRELIDE | 101179262 |
| 240002393 | 240008493 | 1.89 | 92.5 | 03 | 2019-06-17 | 2019-06-23 | Cyclophosphamide+Fludara+TBI Allo | 02 | N | RUXOLITINIB | 100445404 |
| 240002403 | 240008495 | 1.62 | 62.7 | Adjuvant (A) | 2018-12-03 | 2019-04-08 | null | 02 | N | DASATINIB | 100824587 |
| 240002415 | 240008497 | 1.6 | 52.9 | 03 | 2018-11-17 | 2018-11-21 | IBRUTINIB | 02 | N | NOT MATCHED | 100564305 |
| 240002418 | 240008499 | 1.78 | 74 | 03 | 2021-07-04 | 2021-07-13 | AML MyeChild 01 FLA-Idarubicin | 02 | N | ALL UKALL2011 CAP INT MAINT C | 100515222 |
| 240002423 | 240008502 | 1.74 | 102 | null | 2018-08-14 | 2018-08-30 | null | 02 | null | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100602549 |
| 240002426 | 240008504 | 1.63 | 43 | Disease modification (D) | 2021-09-30 | 2021-09-30 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE | 100918603 |
| 240002427 | 240008505 | 1.79 | 19.85 | Curative (C) | 2019-08-08 | 2019-08-15 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100828896 |
| 240002429 | 240008507 | 1.75 | 85 | Palliative (P) | 2018-11-27 | 2019-02-01 | AML MyeChild 01 IT Cyt | N | null | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + FLUDARABINE | 100820324 |
| 240002430 | 240008508 | null | 78.7 | Adjuvant (A) | null | 2020-01-09 | FLAG + Idarubicin | 01 | null | CYCLOPHOSPHAMIDE | 100702960 |
| 240002431 | 240008509 | 1.79 | 88.1 | Disease modification (D) | 2020-01-29 | 2020-03-08 | DA 3+8 | 02 | null | NHL 2003 GP B COP | 101729725 |
| 240002434 | 240008510 | 1.74 | 0 | null | 2018-04-02 | 2018-05-14 | null | 02 | null | ALL UKALL2011 DEL INT A | 100812746 |
| 240002437 | 240008511 | 1.63 | 91.9 | Palliative (P) | 2021-10-11 | 2022-01-09 | AML16 DA 3+10 | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101505664 |
| 240002438 | 240008512 | 1.74 | 88.6 | null | 2019-05-25 | 2019-05-28 | Cytarabine + Idarubicin | 02 | null | AML MYECHILD 01 IT CYT | 101083728 |
| 240002443 | 240008513 | 1.78 | 91.7 | Curative (C) | 2018-10-02 | 2018-10-02 | MATRIX (lymphoma) | 02 | N | AML MYECHILD 01 IT CYT | 101598345 |
| 240002444 | 240008514 | 0 | 73.7 | Curative (C) | 2019-05-03 | 2019-05-05 | AML Int Guide HD Cytarabine (3 + 4) | 01 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100239144 |
| 240002447 | 240008517 | 1.73 | 15.75 | Palliative (P) | 2017-04-29 | 2017-05-11 | null | 01 | N | PEG INTERFERON | 100679385 |
| 240002448 | 240008518 | 0 | 87.4 | Curative (C) | 2019-01-27 | 2019-01-29 | IBRUTINIB | 02 | N | NOT MATCHED | 100616707 |
| 240002449 | 240008519 | 1.73 | 0 | null | 2015-10-21 | 2015-10-24 | AML Interim Guidelines FLAG-Ida | 02 | null | CNS LOW GRADE GLIOMA VINBLASTINE | 100365555 |
| 240002452 | 240008520 | 1.65 | 79.1 | null | 2016-09-13 | 2016-09-23 | null | 02 | null | PENTOSTATIN | 100463616 |
| 240002453 | 240008521 | 1 | 105 | Palliative (P) | null | 2016-12-04 | CVP R | null | N | CYTARABINE + FLUDARABINE + IDARUBICIN | 100564439 |
| 240002457 | 240008523 | 1.55 | 61 | 03 | 2016-02-17 | 2016-03-23 | AML MyeChild 01 FLA-Idarubicin | 01 | null | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | 100387825 |
| 240002458 | 240008524 | 1.62 | 96.25 | 03 | null | 2018-06-14 | null | null | null | IBRUTINIB | 101461048 |
| 240002460 | 240008525 | 1.77 | 84.8 | null | 2021-06-01 | 2021-06-13 | Venetoclax | 02 | null | ANTI-THYMOCYTE GLOBULIN + BUSULFAN + FLUDARABINE | 101381163 |
| 240002472 | 240008527 | 1.55 | 80.9 | Palliative (P) | 2020-02-20 | 2020-02-20 | FLAG + Idarubicin | 02 | N | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 100991995 |
| 240002475 | 240008529 | 1.88 | 72 | null | null | 2018-12-14 | ALL UKALL2011 Maintenance A1 | N | N | AZACITIDINE + VENETOCLAX | 101163175 |
| 240002477 | 240008530 | 0 | 47 | Disease modification (D) | 2016-12-29 | 2016-12-29 | FLAG + Idarubicin | 02 | N | TRANSPLANT CAR-T CELLS - AXICABTAGENE CILOLEUCEL | 100865088 |
| 240002478 | 240008531 | 1.79 | 71 | null | null | 2018-01-29 | IBRUTINIB | N | null | CYCLOPHOSPHAMIDE + FLUDARABINE | 100059700 |
| 240002487 | 240008535 | 1.65 | 70.9 | null | 2018-08-01 | 2018-08-16 | null | 02 | null | FLAIR TRIAL | 100475949 |
| 240002492 | 240008537 | 1.67 | 82 | 03 | 2017-11-30 | 2017-12-05 | null | 02 | N | CYTARABINE + FLUDARABINE | 101353212 |
| 240002494 | 240008539 | 1.74 | 81.1 | 03 | 2019-03-21 | 2019-03-21 | IBRUTINIB | 02 | null | RUXOLITINIB | 101692205 |
| 240002496 | 240008541 | 0 | 19.85 | null | 2017-10-24 | 2017-10-24 | Cytarabine High Dose | 02 | Y | IMATINIB | 101701485 |
| 240002497 | 240008542 | 1.62 | 87.5 | Curative (C) | 2021-06-15 | 2021-10-24 | Midostaurin | 02 | N | MELPHALAN | 101306815 |
| 240002501 | 240008544 | 1.64 | 74.4 | null | 2021-12-14 | 2021-12-14 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 100078158 |
| 240002518 | 240008550 | 1.63 | 68.5 | null | null | 2019-05-27 | Cyclophosphamide+Fludara+TBI Allo | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101274491 |
| 240002522 | 240008552 | 1.69 | 89.8 | Curative (C) | null | 2017-11-15 | null | null | N | CLADRIBINE | 100113108 |
| 240002525 | 240008553 | 1.8 | 57.9 | Curative (C) | 2020-06-01 | 2020-06-04 | null | Y | null | CISPLATIN + GEMCITABINE | 101402408 |
| 240002527 | 240008554 | 1.55 | 67 | Curative (C) | 2020-03-27 | 2020-04-10 | null | 02 | N | RUXOLITINIB | 101474928 |
| 240002528 | 240008555 | null | null | 03 | 2016-05-27 | 2016-08-05 | Rituximab + Venetoclax | null | null | IMATINIB | 101529663 |
| 240002530 | 240008557 | 1.62 | 84 | null | 2016-03-27 | 2016-03-27 | CNS Low Grade Glioma Vinblastine | 02 | N | VENETOCLAX | 101456655 |
| 240002531 | 240008558 | 1.54 | 82.3 | null | 2018-07-04 | 2018-07-24 | Triple / Double Intrathecal Therapy + hydrocortisone | 02 | null | RUXOLITINIB | 101194161 |
| 240002532 | 240008559 | 1.58 | 70.6 | Curative (C) | 2019-04-25 | 2019-04-25 | AML Interim Guidelines FLA -Ida | 02 | N | PEG INTERFERON | 100335586 |
| 240002539 | 240008562 | 1.83 | 55.9 | null | 2018-10-04 | 2018-10-12 | DA 3+8 | 02 | N | AML MYECHILD 01 A MITOZANTRONE/CYTARABINE | 100615225 |
| 240002540 | 240008563 | 1.6 | 76.6 | Palliative (P) | 2021-04-06 | 2021-04-09 | IDELALISIB + RITUXIMAB | 02 | null | CISPLATIN + GEMCITABINE | 101825739 |